Short Interest in Apollomics, Inc. (NASDAQ:APLM) Decreases By 28.8%

Apollomics, Inc. (NASDAQ:APLM) was the recipient of a significant decrease in short interest during the month of January. As of January 31st, there was short interest totalling 3,700 shares, a decrease of 28.8% from the January 15th total of 5,200 shares. Currently, 0.5% of the shares of the company are sold short. Based on an average daily trading volume, of 310,000 shares, the short-interest ratio is currently 0.0 days.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Apollomics stock. Exchange Traded Concepts LLC raised its stake in Apollomics, Inc. (NASDAQ:APLM) by 247.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,259,117 shares of the company’s stock after acquiring an additional 896,316 shares during the quarter. Exchange Traded Concepts LLC owned approximately 1.41% of Apollomics worth $179,000 at the end of the most recent reporting period. 19.13% of the stock is owned by institutional investors and hedge funds.

Apollomics Trading Up 0.7 %

Shares of NASDAQ APLM opened at $7.22 on Friday. The business’s 50 day moving average price is $9.16 and its 200 day moving average price is $11.78. Apollomics has a 52 week low of $6.38 and a 52 week high of $80.50.

About Apollomics

Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.